22/10/2026 AbbVie’s lutikizumab met the primary endpoint in a Ph3 study for HS AbbVie’s lutikizumab met the primary endpoint in a Ph3 study for HS (Ref) AbbVie announced positive topline results from the Ph3 INTREPID trial evaluating lutikizumab (IL-1α/1β antagonist) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint of HiSCR75 at Week 16 as well as 8 ranked secondary endpoints, including improvement in HS-rel